Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
HIF-2α inhibitor (specialist)

Belzutifan

Brand names: Welireg

Belzutifan is an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor used in von Hippel-Lindau disease-associated tumours and in advanced renal cell carcinoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits HIF-2α, a transcription factor that drives expression of genes promoting tumour growth and angiogenesis, particularly in tumours with VHL pathway dysregulation.

Prescribing in practice

  • It commonly causes anaemia and hypoxia, which can be severe, so haemoglobin and oxygen saturation must be monitored and managed during treatment.
  • It is a specialist oncology medicine initiated and supervised within cancer services.
  • It may reduce the effectiveness of hormonal contraception, so additional or alternative contraception is advised.

Monitoring

Monitor haemoglobin and oxygen saturation before and periodically during treatment, with dose adjustment as set out in current prescribing references.

Counselling the patient

  • Report increasing tiredness, breathlessness or paleness, which may indicate anaemia or low oxygen levels.
  • Use additional contraception, as this medicine can make hormonal contraceptives less reliable.

Evidence & guidelines

Belzutifan is supported by clinical trial evidence in von Hippel-Lindau-associated tumours and advanced renal cell carcinoma.

Reference: NICE TA evaluation; ESMO RCC; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways